(secondQuint)Nasal Human Abuse Potential of PTI-821.

 The nasal human abuse liability of PTI-821 will be compared to oxycodone IR using pharmacokinetic and pharmacodynamic assessments.

 A comparison to OxyContin will be dose using pharmacokinetic assessments.

.

 Nasal Human Abuse Potential of PTI-821@highlight

The study will evaluate the human abuse liability of PTI-821 (oxycodone extended-release capsules) when administered nasally compared to crushed oxycodone IR tablets and crushed OxyContin tablets, also administered nasally.

